Calquence 100 mg, containing the active ingredient Acalabrutinib, is a next-generation Bruton’s Tyrosine Kinase (BTK) inhibitor developed by AstraZeneca. It is specifically designed to treat various B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Mantle Cell Lymphoma (MCL). As a selective BTK inhibitor, Calquence stands out due to its precision, minimizing off-target effects and improving patient tolerability compared to older-generation BTK inhibitors.
Key Product Details:
- Active Ingredient: Acalabrutinib 100 mg
- Form: Hard Capsules
- Administration: Oral use
- Packaging: 56 Capsules per box
- Manufacturer: AstraZeneca
Benefits of Calquence 100 mg:
- Highly Selective BTK Inhibition: Targets the BTK enzyme with greater selectivity, reducing side effects associated with non-selective inhibitors.
- Superior Tolerability: Patients experience fewer gastrointestinal and cardiovascular issues compared to older therapies.
- Enhanced Patient Quality of Life: Reduced toxicity leads to better long-term treatment adherence.
- Proven Efficacy: Demonstrates high response rates and prolonged progression-free survival in patients with CLL, SLL, and MCL.
- Reduced Risk of Bleeding: Lower bleeding risk compared to first-generation BTK inhibitors like Ibrutinib.
Indications:
- Chronic Lymphocytic Leukemia (CLL): As monotherapy or in combination with obinutuzumab.
- Small Lymphocytic Lymphoma (SLL): Approved for treating SLL, often alongside other immunotherapy agents.
- Mantle Cell Lymphoma (MCL): Indicated for patients who have received at least one prior therapy.
How Does Calquence 100 mg Work?
Calquence (Acalabrutinib) irreversibly binds to Bruton’s Tyrosine Kinase (BTK), a critical enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, Calquence:
- Blocks B-cell proliferation and survival.
- Reduces the spread of malignant B-cells.
- Inhibits downstream pathways essential for tumor growth.
Dosage and Administration:
- Recommended Dose: 100 mg twice daily (approximately every 12 hours).
- Duration: Continue until disease progression or unacceptable toxicity.
- Administration: Swallow capsules whole with water; do not open, chew, or crush.
Important Safety Information:
- Common Side Effects: Headache, fatigue, diarrhea, upper respiratory tract infection, and bruising.
- Severe Risks: Risk of bleeding, infections, atrial fibrillation, and second primary malignancies.
- Drug Interactions: Avoid strong CYP3A inhibitors and inducers, as they may affect Acalabrutinib levels.
Storage Instructions:
- Temperature: Store below 30°C in the original packaging.
- Handling: Protect from moisture and light.
Why Choose Calquence 100 mg?
Calquence 100 mg offers a groundbreaking approach to treating B-cell malignancies, especially for patients seeking a highly selective, better-tolerated BTK inhibitor. Its targeted action not only controls the disease effectively but also minimizes adverse effects, ensuring improved patient outcomes and quality of life.
Buy Calquence 100 mg Online:
Looking to purchase Calquence 100 mg (Acalabrutinib Hard Capsules) from a trusted source? We provide authentic AstraZeneca products with guaranteed worldwide delivery. Order today and access the latest advancement in B-cell lymphoma and leukemia treatment.
Değerlendirmeler
Henüz değerlendirme yapılmadı.